Drug-Resistant Tuberculosis A Glance at Progress and Global Challenges

Multidrug-resistant Mycobacterium tuberculosis is a major public health threat in many countries, and its management poses a significant economic burden, especially in resource-limited areas. Treatment requires a programmatic approach with access to laboratory services, an array of second-line medications, and adequate clinical resources. The landscape of multidrug-resistant M tuberculosis has undergone major changes within recent years. We have seen rapid developments in diagnostic techniques with whole genome sequencing-based drug susceptibility prediction now in reach, an array of new drugs that transform treatment regimens to purely oral formulations, and a steady stream of multinational trials that inform us about most efficient combinations. Our hope is that the current momentum continues to keep the ambitious goal to end tuberculosis in 2030 in reach.